Business
Appointment of Chairman
Appointment of Chairman.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \n \n RNS Number : 8330N\n Shield Therapeutics PLC\n 26 May 2020\n \n \n \n \n Shield Therapeutics plc\n \n \n (\"Shield\" or the \"Group\" or the \"Company\")\n \n \n \n \n \n Appointment of Chairman\n \n \n \n \n \n \n London, UK, 26 May 2020: \n \n Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product \n Feraccru\n ®\n /Accrufer\n \n \n ®\n \n \n (ferric maltol),\n announces the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting ('AGM') on 18 June 2020. \n \n \n \n \n \n As announced on 21 May 2020, James Karis, the Company's current Chairman, informed the Company that he would not seek re-election and would be stepping down at the AGM on 18 June 2020. Hans Peter Hasler has therefore been appointed with effect from the AGM. Hans Peter joined Shield's Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee. Hans Peter has prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA. He is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston.\n \n \n \n \n \n \n Hans Peter Hasler said: \n \n \n \"I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru®/ Accrufer® is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours.\"\n \n \n \n \n \n \n \n Tim Watts, CEO of Shield Therapeutics, said:\n \n \n \"I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally.\"\n \n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \...